T1	Participants 176 313	patients of subcutaneous sumatriptan 6 mg, administered using a novel cartridge system self-injector, for the acute treatment of migraine
T2	Participants 315 330	Eighty patients
T3	Participants 1762 1800	patients using the novel self-injector
